FDA May Modify Or Halt Review Of Warning Letters By Office Of Chief Counsel
This article was originally published in The Gray Sheet
Executive Summary
FDA is reexamining the role that its Office of Chief Counsel (OCC) plays in the review of warning letters that include quality system violations
You may also be interested in...
FDA's New Enforcement Approach Will Put More Warning Letters In The Mail
FDA Commissioner Margaret Hamburg is honing the agency's enforcement system to get warning letters out faster and create a formal "close-out" process that publicly indicates when a firm has addressed FDA's concerns
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?